EA201190237A1 - Аналоги изоксазол-3(2н)-она в качестве терапевтических агентов - Google Patents

Аналоги изоксазол-3(2н)-она в качестве терапевтических агентов

Info

Publication number
EA201190237A1
EA201190237A1 EA201190237A EA201190237A EA201190237A1 EA 201190237 A1 EA201190237 A1 EA 201190237A1 EA 201190237 A EA201190237 A EA 201190237A EA 201190237 A EA201190237 A EA 201190237A EA 201190237 A1 EA201190237 A1 EA 201190237A1
Authority
EA
Eurasian Patent Office
Prior art keywords
alkyl
optionally substituted
deuterium
heteroaryl
aryl
Prior art date
Application number
EA201190237A
Other languages
English (en)
Other versions
EA020825B1 (ru
Inventor
Йонас Бострём
Лейфенг Ченг
Томас Фекс
Михель Карле
Даниель Петтерсен
Петер Шелль
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of EA201190237A1 publication Critical patent/EA201190237A1/ru
Publication of EA020825B1 publication Critical patent/EA020825B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Соединение I или его фармацевтически приемлемая соль, где R1 и R2 независимо представляют собой водород, дейтерий, арил, гетероарил, C-C-алкил, возможно замещенный одним или более заместителями, независимо представляющими собой R3, R3 представляет собой арил, гетероарил, фтор, C-C-алкил, содержащий один или более чем один фтор, C-C-алкил, содержащий один или более чем один дейтерий, C-C-алкил, содержащий гидрокси, где арил и гетероарил возможно замещены одним или более чем одним галогеном, фторированным алкокси, фторированным алкилом, сульфонилом, одним или более чем одним дейтерием, Cалкилом, Cалкокси, нитрилом, или R3 представляет собой C-алкил, возможно замещенный одной или более из следующих групп: COOR4, OCOR4, CONR5R6, NR5COR6, OR4; где R4 представляет собой Cалкил, возможно замещенный одним или более чем одним фтором, дейтерием, алкокси, арилкарбоксилатом, алкилкарбоксилатом; R5 и R6 независимо выбраны из водорода, алкила или они могут вместе образовывать 4-8-членное углеродное кольцо; или R1 и R2 образуют 3-10-членное углеродное кольцо, возможно содержащее О или N и возможно замещенное Cалкилом или арилом, гетероарилом, возможно замещенным R3.
EA201190237A 2009-04-07 2010-04-06 Аналоги изоксазол-3(2h)-она в качестве терапевтических агентов EA020825B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16722409P 2009-04-07 2009-04-07
US17195609P 2009-04-23 2009-04-23
PCT/SE2010/050375 WO2010117323A1 (en) 2009-04-07 2010-04-06 Method and apparatus for producing heat energy and carbon dioxide

Publications (2)

Publication Number Publication Date
EA201190237A1 true EA201190237A1 (ru) 2012-04-30
EA020825B1 EA020825B1 (ru) 2015-02-27

Family

ID=42934883

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201190237A EA020825B1 (ru) 2009-04-07 2010-04-06 Аналоги изоксазол-3(2h)-она в качестве терапевтических агентов

Country Status (21)

Country Link
US (1) US8415378B2 (ru)
EP (1) EP2417131A4 (ru)
JP (1) JP5711723B2 (ru)
KR (1) KR101675607B1 (ru)
CN (1) CN102459246B (ru)
AR (1) AR076219A1 (ru)
AU (1) AU2010235236B2 (ru)
BR (1) BRPI1013984A2 (ru)
CA (1) CA2757879C (ru)
CO (1) CO6440580A2 (ru)
CU (1) CU20110190A7 (ru)
EA (1) EA020825B1 (ru)
EC (1) ECSP11011385A (ru)
IL (1) IL215336A0 (ru)
MX (1) MX2011010647A (ru)
NI (1) NI201100181A (ru)
SG (1) SG174463A1 (ru)
TW (1) TW201040166A (ru)
UY (1) UY32543A (ru)
WO (1) WO2010117323A1 (ru)
ZA (1) ZA201108119B (ru)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0916576A2 (pt) 2008-08-04 2017-06-27 Chdi Inc pelo menos uma entidade química, composição farmacêutica, e, método para tratar uma condição ou distúrbio.
NZ601547A (en) 2010-01-25 2014-04-30 Chdi Foundation Inc Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2012047156A1 (en) * 2010-10-04 2012-04-12 Astrazeneca Ab Isoxazol-3(2h)-one analogs as plasminogen inhibitors and their use in the treatment of fibrinolysis related diseases
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
SG2014012926A (en) * 2011-08-30 2014-06-27 Chdi Foundation Inc Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2013033068A1 (en) 2011-08-30 2013-03-07 Stephen Martin Courtney Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
US9073881B2 (en) 2011-09-23 2015-07-07 Hoffmann-La Roche Inc. Benzoic acid derivatives
CA2876689C (en) 2012-06-13 2022-04-26 Incyte Corporation Substituted tricyclic compounds as fgfr inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
CN102977050B (zh) * 2012-11-20 2015-04-22 浙江工业大学 一种2-苯并噻唑二甲缩醛和2-苯并噻唑甲醛的合成方法
CN102977040B (zh) * 2012-11-20 2015-06-03 浙江工业大学 一种2-喹喔啉基二甲缩醛和2-喹喔啉基甲醛的合成方法
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
PH12015502383B1 (en) 2013-04-19 2023-02-03 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
UY35809A (es) 2013-11-05 2015-05-29 Bayer Pharma AG (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos
MX372995B (es) 2014-07-17 2020-04-13 Chdi Foundation Inc Metodos y composiciones para el tratamiento de trastornos relacionados con vih.
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EP3215505B1 (en) 2014-11-03 2019-07-24 Bayer Pharma Aktiengesellschaft Piperidinylpyrazolopyrimidinones and their use
BR112017008835A2 (pt) 2014-12-19 2018-03-27 Emeriti Pharma Ab composto, e, composição farmacêutica.
CA2976790C (en) 2015-02-20 2024-02-27 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CN104725300A (zh) * 2015-02-28 2015-06-24 宁波九胜创新医药科技有限公司 一种1-(6-甲基吡啶-3-基)-2-(4-甲磺酰基苯基)乙酮的制备方法
WO2016173948A1 (en) 2015-04-30 2016-11-03 Bayer Pharma Aktiengesellschaft Indazolopyrimidinones as fibrinolysis inhibitors
CN107459514B (zh) * 2016-06-06 2020-10-23 南开大学 一类手性哌啶衍生物及其制备方法和用途
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN107857725A (zh) * 2017-12-19 2018-03-30 苏州艾缇克药物化学有限公司 一种2‑氨基吡啶‑4‑甲醇的合成方法
KR102956194B1 (ko) 2018-05-04 2026-04-23 인사이트 코포레이션 Fgfr 억제제의 염
RS66310B1 (sr) 2018-05-04 2025-01-31 Incyte Corp Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
GEP20247679B (en) 2019-10-14 2024-10-10 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
MX2022006691A (es) 2019-12-04 2022-09-19 Incyte Corp Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr).
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN121248675A (zh) 2020-12-31 2026-01-02 赛诺哈勃药业(成都)有限公司 一种纤溶酶抑制剂、其制备方法及应用
JP7749679B2 (ja) * 2021-02-05 2025-10-06 シンノハブ ファーマシューティカル カンパニー,リミティド プラスミン阻害剤、その製造方法およびその適用
EP4323405A1 (en) 2021-04-12 2024-02-21 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
TW202313610A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為fgfr抑制劑之三環雜環
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2174838A1 (en) 1993-11-24 1995-06-01 John Wityak Novel isoxazoline and isoxazole fibrinogen receptor antagonists
WO2000029406A2 (en) 1998-11-18 2000-05-25 Du Pont Pharmaceuticals Company Novel isoxazoline fibrinogen receptor antagonists
US20030207873A1 (en) * 2002-04-10 2003-11-06 Edmund Harrington Inhibitors of Src and other protein kinases
AU2004231087B2 (en) * 2003-04-15 2007-01-04 Merck Sharp & Dohme Corp. Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors
US7598243B2 (en) * 2003-04-17 2009-10-06 Merck & Co., Inc. Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity
CN101328173B (zh) * 2008-07-31 2010-12-15 石药集团欧意药业有限公司 一种制备6-氟-3-(4-哌啶基)-1,2-苯并异噁唑盐酸盐的方法

Also Published As

Publication number Publication date
NI201100181A (es) 2012-06-14
IL215336A0 (en) 2011-12-29
ECSP11011385A (es) 2011-11-30
MX2011010647A (es) 2012-02-21
CN102459246B (zh) 2014-05-07
AU2010235236A1 (en) 2011-10-20
JP2012522836A (ja) 2012-09-27
KR101675607B1 (ko) 2016-11-11
ZA201108119B (en) 2012-07-25
EA020825B1 (ru) 2015-02-27
US8415378B2 (en) 2013-04-09
EP2417131A1 (en) 2012-02-15
TW201040166A (en) 2010-11-16
KR20120034611A (ko) 2012-04-12
CO6440580A2 (es) 2012-05-15
JP5711723B2 (ja) 2015-05-07
UY32543A (es) 2010-11-30
US20100261755A1 (en) 2010-10-14
CA2757879C (en) 2017-06-06
CA2757879A1 (en) 2010-10-14
WO2010117323A8 (en) 2010-11-18
AU2010235236B2 (en) 2013-10-24
EP2417131A4 (en) 2014-08-27
CN102459246A (zh) 2012-05-16
SG174463A1 (en) 2011-10-28
AR076219A1 (es) 2011-05-26
WO2010117323A1 (en) 2010-10-14
CU20110190A7 (es) 2012-02-15
BRPI1013984A2 (pt) 2018-06-19

Similar Documents

Publication Publication Date Title
MX2011010647A (es) Analogos de isoxasol-3 (2h)-ona como agentes terapeuticos.
EA201070872A1 (ru) Производные азабициклических карбоксамидов, их получение и их применение в терапии
EA201170237A1 (ru) Производные карбаматов алкилтиазолов, их получение и их применение в терапии
AR054130A1 (es) Procedimiento para la preparacion de 1-alquil-3-feniluracilos
EA201070871A1 (ru) Бициклические производные азабициклических карбоксамидов, их получение и их применение в терапии
AR078833A1 (es) Derivados de heteroarilos que contienen nitrogeno como inhibidores dela cinasa jak3
EA201171387A1 (ru) Производные 7-азаспиро[3,5]нонан-7-карбоксилатов, их получение и их применение в терапии
EA201791781A1 (ru) Производные замещенного моно- и полиазанафталина и их применение
MA38540B1 (fr) Dérivés de naphtyridine utiles comme antagonistes de l'intégrine alpha-v-bêta-6
MX2021002199A (es) Inhibidores de sarcomeros cardiacos.
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
EA201490831A1 (ru) Способ получения хинолиновых производных
AR061642A1 (es) Derivados de ureas de tropano, su preparacion y su aplicacion en terapeu-tica, procesos de obtencion y composiciones farmaceuticas
EA201170096A1 (ru) Замещенные производные пиримидона
EA201171386A1 (ru) ПРОИЗВОДНЫЕ ЦИКЛОПЕНТА[c]ПИРРОЛ-2-КАРБОКСИЛАТОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ
RU2012105122A (ru) Способ получения хиральных производных 3-триазолилсульфоксида
EA201490722A1 (ru) ПРОИЗВОДНЫЕ ЭТИНИЛА В КАЧЕСТВЕ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ МЕТАБОТРОПНОГО РЕЦЕПТОРА ГЛУТАМАТА mGluR5
AR068849A1 (es) Procedimiento para la preparacion de diamidas de acido sulfonico
AR072431A1 (es) Procedimiento mejorado para la preparacion de 2-trifluormetil-5-(1-substituido)alquilpiridina
CY1116391T1 (el) Αιθινυλο παραγωγα ως θετικοι αλλοστερικοι ρυθμιστες του mglur5
PE20151977A1 (es) Nuevos derivados de purina
EA201391541A1 (ru) 5-(фенил/пиридинил-этинил)-2-пиридин/ 2-пиримидин-карбоксамиды в качестве модуляторов mglur5
BR112014004275A2 (pt) derivados de isoxazolina como compostos inseticidas
EA201690408A1 (ru) Производные этинила
EA200701470A1 (ru) Способы получения производных 4-(фенокси-5-метилпиримидин-4-илокси)пиперидин-1-карбоновой кислоты и родственных соединений

Legal Events

Date Code Title Description
PC1A Registration of transfer to a eurasian application by force of assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): KG MD TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ TJ

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU